Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 6/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14434989 | 0.78 | CYP1A2 (0.50) | KDM4EDGAT1CYP3A4MEN1CYP1A2 | |
| SCHEMBL1231879 | 0.75 | KDM4E (0.43) | KDM4EDGAT1CYP3A4MEN1CYP1A2 | |
| SCHEMBL1018843 | 0.74 | DGAT1 (0.37) | KDM4EDGAT1CYP3A4MEN1CYP1A2 | |
| SCHEMBL558229 | 0.69 | PIK3CA (0.41) | ASIC3KMOPI4KBEGFRPIK3CD | |
| SCHEMBL3804688 | 0.69 | DGAT1 (0.47) | KDM4EDGAT1CYP3A4MEN1CYP1A2 | |
| SCHEMBL30448395 | 0.68 | HSP90AA1 (0.58) | ASIC3KDM4EKMOMEN1KMT2A | |
| SCHEMBL19053832 | 0.68 | KDM4E (0.50) | KDM4EDGAT1CYP3A4MEN1CYP1A2 | |
| SCHEMBL558575 | 0.67 | HSP90AA1 (0.46) | ASIC3KDM4EKMOHSP90AA1CA2 | |
| SCHEMBL22838434 | 0.65 | ASIC3 (0.59) | ASIC3KMOHSP90AA1CA2CHKA | |
| SCHEMBL125453 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110045511-A1 | METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHOD | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | claimed |
| EP-2271943-A1 | METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHODS | Novartis AG (CH) | 2011-01-12 | — | — | EP | claimed |
| WO-2009133101-A1 | METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHODS | NOVARTIS AG (CH) | 2009-11-05 | — | — | WO | claimed |
| US-20150323548-A1 | METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHODS | NOVARTIS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| CN-101511798-B | [4,5'] bipyrimidinyl-6, 4' -diamine derivatives as protein kinase inhibitors | IRM LLC | 2011-11-02 | — | — | CN | disclosed |
| US-8026243-B2 | [4,5′]Bipyrimidinyl-6,4′-diamine derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | disclosed |
| US-20110045511-A1 | METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHOD | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| EP-2271943-A1 | METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHODS | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100234376-A1 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors | NOVARTIS AG | 2010-09-16 | — | — | US | disclosed |
| WO-2009133101-A1 | METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHODS | NOVARTIS AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| CN-101511798-A | [4, 5 '] bipyrimidinyl-6, 4' -diamine derivatives as protein kinase inhibitors | IRM LLC (VG) | 2009-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234376-A1 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors | FGFR3, ERBB2, ERBB4 | ASIC3 961/4885KDM4E 402/4885DGAT1 3491/4885 |
| US-20150323548-A1 | METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHODS | FGF23, FGFR3, FGFR1 | ASIC3 327/4885KDM4E 3592/4885DGAT1 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.